Overview
Compare with NEONC TECHNOLOGIES HOLDINGS, INC., Altimmune, Inc. or ORAGENICS INC, or pick any stock.
- TickerAXIM on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersSan Diego, California1
- Incorporated inNV2
- Business address6191 Cornerstone Court, E, Suite 114, San Diego, Ca 921212
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Axim Biotechnologies, Inc., a Nevada corporation, is a leading developer of diagnostic healthcare solutions serving to enhance the health of people. Through the development of diagnostic solutions that quickly and accurately diagnose various diseases, our products allow healthcare workers to quickly test and treat at the point-of-care, which leads to improved patient outcomes and provides numerous economic benefits to the healthcare system.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2023
Where the money goes
Where each dollar of revenue went, fiscal 2023
- Research and development5¢$125.5K
- Selling, general and admin92¢$2.2M
- Interest2¢$57.8K
Out of $39.5K in revenue.4 The company lost money this year.
Financial statements
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | $47.6K5 | $195.6K6 | $799.5K6 | $07 | $60.5K8 | $8.9K4 | $39.5K4 |
| Cost of revenue | $42.9K5 | $8.5K6 | $09 | $09 | |||
| Gross profit | $4.7K5 | $187.1K6 | $09 | $09 | |||
| Research and development | $1.4M5 | $2.1M6 | $09 | $426.7K7 | $284.9K11 | $153.7K4 | $125.5K4 |
| Selling, general and admin | $5.7M8 | $4.1M4 | $2.2M4 | ||||
| Operating expenses | $14.0M8 | $4.7M4 | $2.8M4 | ||||
| Operating income | -$3.1M5 | -$5.0M6 | -$3.1M9 | -$4.9M7 | -$14.0M8 | -$4.7M4 | -$2.8M4 |
| Interest | $315.0K5 | $456.1K6 | $222.2K9 | $234.8K7 | $247.8K7 | $57.8K12 | |
| Income before tax | -$16.0M8 | -$6.2M4 | -$8.1M4 | ||||
| Income tax | $05 | $06 | $09 | $07 | $08 | $04 | $04 |
| Net income | -$4.2M5 | -$6.8M6 | -$6.4M9 | -$6.4M7 | -$16.0M8 | -$6.2M4 | -$8.1M4 |
| Earnings per share | -$0.109 | -$0.067 | $0.128 | -$0.044 | -$0.044 | ||
| Earnings per share (diluted) | -$0.109 | -$0.067 | $0.128 | -$0.044 | -$0.044 |
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash | $2.1M6 | $1.8M9 | $511.6K7 | $457.2K7 | $453.0K8 | $47.3K8 | $156.5K4 |
| Current assets | $2.1M5 | $2.0M6 | $1.6M9 | $713.1K7 | $636.6K8 | $104.0K4 | $156.5K4 |
| Property, plant and equipment | $116.8K8 | $93.8K4 | $134.1K4 | ||||
| Goodwill | $07 | ||||||
| Total assets | $2.2M5 | $2.1M6 | $1.7M9 | $11.3M7 | $5.3M8 | $4.2M4 | $4.1M4 |
| Short-term debt | $1807 | ||||||
| Current liabilities | $7.7M5 | $3.3M6 | $3.4M9 | $1.5M7 | $2.6M8 | $3.4M4 | $6.0M4 |
| Long-term liabilities | $5.1M8 | $5.6M4 | $5.8M4 | ||||
| Total liabilities | $8.5M5 | $8.2M6 | $8.5M9 | $9.7M7 | $7.7M8 | $9.0M4 | $11.8M4 |
| Retained earnings | -$57.9M8 | -$64.1M4 | -$72.2M4 | ||||
| Shareholders’ equity | -$6.3M6 | -$6.1M9 | -$6.8M7 | $1.6M8 | -$2.3M4 | -$4.8M4 | -$7.7M4 |
| Shares outstanding | 54.6M shares5 | 59.6M shares6 | 64.9M shares9 | 125.3M shares7 | 138.1M shares8 | 192.4M shares4 | 245.9M shares4 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -$5.0M9 | -$3.2M7 | -$2.5M8 | -$2.0M4 | -$1.0M4 | ||
| Depreciation and amortization | $2.1M8 | $426.1K4 | $427.0K4 | ||||
| Stock-based compensation | $1.1M8 | $1.1M4 | $197.7K4 | ||||
| Capital spending | $97.3K7 | $40.5K8 | $8.7K4 | $04 | |||
| Free cash flow | -$3.3M | -$2.5M | -$2.1M | -$1.0M | |||
| Cash from investing | -$50.5K8 | -$8.7K4 | $04 | ||||
| Cash from financing | $2.5M8 | $1.6M4 | $1.1M4 |
Corporate structure
AXIM BIOTECHNOLOGIES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of AXIM BIOTECHNOLOGIES, INC.
- Juniper & Ivy Corp Filed SC 13D on AXIM BIOTECHNOLOGIES, INC., latest Sep 23, 2022
- Catalina Valencia Filed SC 13D/A on AXIM BIOTECHNOLOGIES, INC., latest Aug 31, 2022 (2 filings since Aug 31, 2022)
- Glycodots, LLC Filed SC 13D on AXIM BIOTECHNOLOGIES, INC., latest Aug 31, 2022
- AXIM BIOTECHNOLOGIES, INC. San Diego, California
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What AXIM BIOTECHNOLOGIES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $256.8K4 Dec 31, 2023 | $184.0K4 Dec 31, 2022 | +39.6% |
| Accumulated depreciation | $122.7K4 Dec 31, 2023 | $90.2K4 Dec 31, 2022 | +36.1% |
| Property and equipment, net | $134.1K4 Dec 31, 2023 | $93.8K4 Dec 31, 2022 | +42.9% |
| Operating-lease assets (leased space) | $227.0K4 Dec 31, 2023 | $19.8K4 Dec 31, 2022 | +1047.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $47.3K8 Dec 31, 2022 | $453.0K8 Dec 31, 2021 | −89.6% |
Intangibles and goodwill
Leadership
Who has led AXIM BIOTECHNOLOGIES, INC., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Chief operating officer
- Chief executive officerJohn Walter Huemoeller Ii. Sep 23, 2022 to Mar 19, 202413
- Chief executive officerGeorge Anastassov Feb 15, 2017 to Feb 15, 201714
- Chief executive officerRosemary Samuels Jul 13, 2011 to Apr 30, 201415
- PresidentCatalina Valencia Oct 15, 2024 to Oct 15, 202416
- PresidentGeorge Anastassov Mar 3, 2015 to Feb 5, 201617
- PresidentRosemary Samuels Jul 13, 2011 to Apr 30, 201415
- Chief financial officerRobert Malasek Jun 23, 2017 to Mar 19, 202418
- Chief financial officerRosemary Samuels Jul 13, 2011 to Apr 30, 201415
- Chief operating officerKurt Phinney May 30, 2023 to May 30, 202319
Board members and other officers (8)
- Board memberCatalina Valencia Oct 15, 2024 to Oct 15, 202416
- Board memberPeter O'Rourke Sep 23, 2022 to Mar 19, 202420
- Board memberBlake Schroeder Jun 23, 2017 to Mar 19, 202421
- Board memberJohn Walter Huemoeller Ii. Jun 23, 2017 to Mar 19, 202422
- Board memberRobert L. Cunningham Jun 23, 2017 to Mar 19, 202423
- Board memberGeorge Anastassov Mar 3, 2015 to Feb 15, 201717
- Board memberLekhram Changoer Dec 30, 2015 to Feb 15, 201724
- Board memberRosemary Samuels Jul 13, 2011 to Apr 30, 201415
Former names
- AXIM INTERNATIONAL INC.Mar 10, 2011 to Aug 13, 20142
Timeline
- Oct 15, 20248-K Change in control; Executive or director change25
- Mar 21, 20248-K Entered a material agreement; New debt or obligation26
- Feb 13, 20248-K Entered a material agreement; Unregistered sale of shares27
- Dec 28, 20238-K Entered a material agreement; Unregistered sale of shares28
- Jun 2, 20238-K Entered a material agreement29
- May 30, 20238-K Entered a material agreement; New debt or obligation30
- May 25, 20238-K Executive or director change31
- Jan 27, 20238-K Entered a material agreement; New debt or obligation32
- Sep 23, 2022New chief executive John Walter Huemoeller Ii. becomes CEO13
- Sep 19, 20228-K Entered a material agreement; Regulation FD disclosure33
- Aug 29, 20228-K Entered a material agreement; Unregistered sale of shares34
- Mar 9, 20228-K Ended a material agreement; Regulation FD disclosure35
- Feb 16, 20228-K Entered a material agreement; Ended a material agreement; New debt or obligation36
- Feb 15, 2017New chief executive George Anastassov becomes CEO14
- Jul 13, 2011New chief executive Rosemary Samuels becomes CEO15
Filings
88 filings to the SEC since October 2021: 4 annual reports, 11 quarterly reports, 14 major events, 29 insider forms, 4 large holders, 26 other. The latest 20:
- Dec 6, 202415-12G AXIM BIOTECHNOLOGIES, INC. FORM 15-12G EDGAR
- Nov 13, 2024NT 10-Q AXIM BIOTECHNOLOGIES, INC._FORM NT 10-Q EDGAR
- Oct 15, 20244 PRIMARY DOCUMENT EDGAR
- Oct 15, 20248-K AXIM BIOTECHNOLOGIES, INC. - FORM 8-K SEC FILING EDGAR
- Aug 19, 202410-Q EDGAR
- Aug 13, 2024NT 10-Q AXIM BIOTECHNOLOGIES FORM 12B-25 EDGAR
- May 22, 202410-Q/A EDGAR
- May 20, 202410-Q EDGAR
- May 15, 2024NT 10-Q AXIM BIOTECHNOLOGIES FORM 12B-25 EDGAR
- Apr 16, 202410-K EDGAR
- Apr 1, 2024NT 10-K AXIM BIOTECHNOLOGIES, INC. - NT 10K EDGAR
- Mar 21, 20248-K AXIM BIOTECHNOLOGIES, INC. - FORM 8-K SEC FILING EDGAR
- Mar 19, 20244/A PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
- Mar 19, 20244 PRIMARY DOCUMENT EDGAR
The 88 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 30, 2024 | Valencia CatalinaPresident and Director | Buy | 1,086,216 | Form 4 | ||
| Aug 24, 2022 | Valencia CatalinaPresident and Director | Buy | 3,861,004 | $0.03 | $115.8K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Juniper & Ivy CorpSC 13D, 1 filing Sep 23, 202237
- Catalina ValenciaSC 13D/A, 2 filings Aug 31, 202238
- Glycodots, LLCSC 13D, 1 filing Aug 31, 202239
SEC filer profile
How AXIM BIOTECHNOLOGIES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAXIM BIOTECHNOLOGIES, INC.1
- CIK0001514946
- Employer ID (EIN)27-40929861
- Filer statusNon-accelerated filer<br>smaller reporting company1
- Incorporated inNevada1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address6191 Cornerstone Court, E, Suite 114, San Diego, CA 921211
- Phone(212) 751-00011
- Shares outstanding301,958,824 as of Aug 16, 202411
- Public float$5.3M as of Jun 30, 20234
- On EDGAR sinceMar 10, 20111
- Filings306 in all: 8-K (65), 10-Q (39), NT 10-Q (30), 4 (29), 10-Q/A (17), UPLOAD (17), 3 (16), 10-K (13)1
All 31 form types
CORRESP (11), NT 10-K (10), 10-K/A (8), 5 (6), SC 13D (5), 8-K/A (4), EFFECT (4), 10-12G/A (3), D (3), PRE 14C (3), S-1 (3), SC 13D/A (3), 10-12G (2), 15-12G (2), 424B5 (2), DEF 14C (2), S-1/A (2), S-8 (2), 144 (1), 4/A (1), 5/A (1), PRER14C (1), S-3 (1)
- Latest filingsAnnual report (10-K) Apr 16, 2024
Quarterly report (10-Q) Aug 19, 2024
Latest 8-K (8-K) Oct 15, 2024
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARCatalina Valencia, President
- 17SEC EDGARGeorge Anastassov, President
- 18
- 19
- 20SEC EDGARPeter O'Rourke, Board member
- 21SEC EDGARBlake Schroeder, Board member
- 22
- 23SEC EDGARRobert L. Cunningham, Board member
- 24SEC EDGARLekhram Changoer, Board member
- 25
- 26
- 27
- 28
- 29SEC EDGAREntered a material agreement
- 30
- 31SEC EDGARExecutive or director change
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39